Published in Cancer Weekly, July 15th, 1996
This authorization followed the positive opinion in February 1996 by the Committee of Proprietary and Medicinal Products (CPMP). Caelyx is a long-circulating Stealth liposome formulation of doxorubicin, an anticancer drug. This drug is marketed in the United States under the tradename Doxil.
The approval was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.